pharma · Obesity, Overweight · Type 2 Diabetes
Eli Lilly Co.
Eli Lilly Co is a pharma organization headquartered in EU. Primary therapeutic focus areas include Obesity, Overweight, Type 2 Diabetes, Ulcerative Colitis, Type 2 Diabetes Mellitus, Breast Cancer. NovaPharmaNews links 1
Phase 3 · small molecule · Obesity
Retatrutide is a small-molecule therapeutic candidate in Phase 3 development by Eli Lilly for the treatment of obesity. The program is being evaluated through a randomized, double-blind clinical trial (NCT 2024-511450-49-00) comparing retatrutide efficacy and safety against tirzepatide, Eli Lilly's approved GLP-1 recep
Internal code J1I-MC-GZBP
Retatrutide is a small-molecule therapeutic candidate in Phase 3 development by Eli Lilly for the treatment of obesity. The program is being evaluated through a randomized, double-blind clinical trial (NCT 2024-511450-49-00) comparing retatrutide efficacy and safety against tirzepatide, Eli Lilly's approved GLP-1 receptor agonist and GIP receptor agonist combination therapy marketed as MOUNJARO. Tirzepatide itself has achieved regulatory approval in the European Union (January 2026), Japan (December 2024), and the United States, establishing a validated mechanism for obesity treatment. The retatrutide program represents Eli Lilly's strategy to advance next-generation obesity therapeutics beyond its existing tirzepatide franchise. As of the latest available information, retatrutide remains in active Phase 3 development with no regulatory filing or approval disclosed. The competitive positioning of this program is directly anchored to tirzepatide performance, as the trial design uses tirzepatide as the active comparator rather than placebo, indicating Eli Lilly's confidence in advancing incremental innovation within its obesity portfolio.
Obesity represents a significant unmet medical need with growing prevalence globally and substantial cardiovascular and metabolic comorbidities. The regulatory approval of tirzepatide has validated dual GLP-1/GIP receptor agonism as an effective mechanism, generating substantial commercial interest and market expansion. Retatrutide's development as a potential successor or complementary agent to tirzepatide addresses the need for treatment options with potentially improved efficacy, tolerability, or convenience profiles. The Phase 3 trial design—comparing retatrutide directly to tirzepatide rather than placebo—suggests Eli Lilly is positioning retatrutide as a differentiated advancement, likely targeting superior weight loss or metabolic outcomes. The obesity therapeutics market has demonstrated exceptional commercial potential, with tirzepatide achieving rapid uptake post-approval. Retatrutide's success could extend Eli Lilly's market leadership in obesity treatment and capture additional patient populations or indications. The competitive landscape includes multiple approved agents across different mechanisms (DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 agonists), but the GLP-1/GIP dual-agonist class has emerged as the most efficacious. Retatrutide's clinical development occurs in a market with high unmet need, strong payer interest, and demonstrated patient demand, making regulatory approval and market access critical commercial milestones.
Drug Class: Small-molecule therapeutic candidate; mechanism of action and specific molecular target not yet disclosed.
Modality: Small molecule.
Route of Administration: Not disclosed for retatrutide; comparator tirzepatide is administered subcutaneously.
Related Therapies: Tirzepatide (MOUNJARO), the active comparator in the Phase 3 trial, is a dual GLP-1 receptor agonist and GIP receptor agonist approved for obesity treatment. Tirzepatide is marketed globally with regulatory approvals in the EU, Japan, and US.
Regulatory Status: Retatrutide: Phase 3, active development; no regulatory filing or approval disclosed. Tirzepatide: Approved in EU (EMA/H/C/005620, January 2026), Japan (December 2024), and US (NDA215866, NDA217806).
Patent Status: Not disclosed.
First Approval: Not applicable; retatrutide has not yet been approved.
Also known as: obesity, obesity disease
A disorder involving an excessive amount of body fat.
ClinicalTrials.gov lists 50 registered studies for Obesity (Disorder) (AACT aggregate).
Phase breakdown: NA (46), PHASE4 (3), PHASE3 (1)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0011122), Orphanet — obesity disorder, NCT03412149, NCT06787001, NCT06852391, NCT06881485, NCT06911918, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
Phase 3 Retatrutide vs. Tirzepatide Trial Active
Randomized, double-blind study (NCT 2024-511450-49-00) evaluating efficacy and safety of retatrutide compared to tirzepatide in adults with obesity is ongoing.
The obesity therapeutics market includes multiple approved agents across diverse mechanisms. Competitors identified in the facts include SAXENDA (liraglutide, Teva), a GLP-1 receptor agonist; FORXIGA (dapagliflozin, AstraZeneca) and INVOKANA (canagliflozin, Teva), SGLT2 inhibitors; and DPP-4 inhibitors including TRAJENTA (linagliptin, Boehringer Ingelheim), ONGLYZA (saxagliptin, AstraZeneca), VIPIDIA (vildagliptin, Takeda), and NESINA (alogliptin, Lacuna Pharma). Additional agents include ACTOS (pioglitazone, Alphapharm), REPAGLINIDE SUN (repaglinide, Teva), ZYNQUISTA (canagliflozin/metformin, Lexicon), QTRILMET (teneligliptin/metformin, Takeda), and TRAZEC (troglitazone, Teva). However, tirzepatide's dual GLP-1/GIP agonism has emerged as the most clinically effective mechanism for obesity treatment, establishing a new competitive standard. Retatrutide's Phase 3 trial design—using tirzepatide as the active comparator—indicates Eli Lilly's strategy to differentiate within the GLP-1/GIP class rather than compete against older mechanism classes. The competitive positioning suggests retatrutide is intended as an advancement within Eli Lilly's obesity franchise rather than a response to external competitors, consolidating market leadership in the highest-efficacy therapeutic category.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| TRAJENTA | Boehringer Ingelheim Pty Ltd | — | approved |
| ACTOS | Alphapharm Pty Ltd | — | approved |
| ONGLYZA | AstraZeneca | — | approved |
| VIPIDIA | Takeda | — | approved |
| REPAGLINIDE SUN | Teva Pharma GmbH | — | approved |
| NESINA | Lacuna Pharma Pty Ltd | — | approved |
| ZYNQUISTA | LEXICON PHARMACEUTICALS, INC. | — | approved |
| SAXENDA | Teva Pharma GmbH | — | approved |
| FORXIGA | AstraZeneca | — | approved |
| QTRILMET | Takeda | — | approved |
| TRAZEC | Teva Pharma GmbH | — | approved |
| INVOKANA | Teva Pharma GmbH | — | approved |
| SIBUTRAMINE | — | Monoamine transporter inhibitor | Approved |
| SETMELANOTIDE ACETATE | — | Melanocortin receptor 4 agonist | Approved |
| SETMELANOTIDE | — | Melanocortin receptor 4 agonist | Approved |
| RIMONABANT | — | Cannabinoid CB1 receptor antagonist | Approved |
| PHENTERMINE HYDROCHLORIDE | — | Norepinephrine transporter releasing agent | Approved |
| PHENTERMINE | — | Norepinephrine transporter releasing agent | Approved |
| PHENDIMETRAZINE TARTRATE | — | Norepinephrine transporter inhibitor | Approved |
| ORLISTAT | — | Pancreatic lipase inhibitor | Approved |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
United States (FDA): Retatrutide regulatory status not yet disclosed. Tirzepatide approved via NDA215866 and NDA217806.
European Union (EMA): Retatrutide regulatory status not yet disclosed. Tirzepatide approved January 29, 2026 (EMA/H/C/005620) with marketing authorization holder Eli Lilly Nederland B.V.
Japan (PMDA): Retatrutide regulatory status not yet disclosed. Tirzepatide approved December 2024.
China (NMPA): Regulatory status for both retatrutide and tirzepatide not disclosed in the available facts.
Retatrutide remains in Phase 3 development with no regulatory filing, approval, or timeline disclosed. The program's advancement will depend on Phase 3 trial completion and data review by regulatory authorities.
Retatrutide is a small-molecule therapeutic candidate in Phase 3 development by Eli Lilly for the treatment of obesity. Its specific mechanism of action has not yet been disclosed.
No. Retatrutide is currently in Phase 3 clinical development and has not been submitted for or approved by the FDA. No regulatory filing or approval timeline has been disclosed.
No. Retatrutide has not been approved by the European Medicines Agency (EMA). The program remains in Phase 3 development.
No. Retatrutide has not been approved by the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. Regulatory status remains undisclosed.
Eli Lilly Co. is the sponsor and developer of retatrutide. No manufacturing partners or licensing agreements have been disclosed.
The specific mechanism of action for retatrutide has not been disclosed in available information.
The route of administration for retatrutide has not been disclosed. The comparator therapy, tirzepatide, is administered subcutaneously.
A Phase 3, randomized, double-blind study (NCT 2024-511450-49-00) is comparing retatrutide efficacy and safety to tirzepatide in adults with obesity. Results have not yet been reported.
Retatrutide is being directly compared to tirzepatide in a Phase 3 trial, suggesting Eli Lilly is evaluating potential superiority or differentiation. Tirzepatide is an approved dual GLP-1/GIP receptor agonist marketed as MOUNJARO.
Retatrutide is in Phase 3 clinical development with active enrollment in a comparative efficacy and safety trial. No regulatory filing or approval has been disclosed.
No approval timeline has been disclosed. Regulatory approval depends on Phase 3 trial completion, data review, and regulatory authority decisions.
Retatrutide is in development for the treatment of obesity in adults.
No brand name has been disclosed for retatrutide, as the drug has not yet been approved for marketing.
The internal code for the retatrutide development program is J1I-MC-GZBP.
No partners or licensing agreements have been disclosed. Eli Lilly Co. is the sole sponsor of the retatrutide program.
Approved competitors include tirzepatide (MOUNJARO, Eli Lilly), liraglutide (SAXENDA, Teva), SGLT2 inhibitors (FORXIGA, INVOKANA), and DPP-4 inhibitors (TRAJENTA, ONGLYZA, VIPIDIA, NESINA). Tirzepatide represents the most clinically effective approved option.
Retatrutide is classified as a small-molecule therapeutic candidate.
J1I-MC-GZBP → Drug → Target → Indication → Company → Trials → Competitors
Strategic Implications: Retatrutide represents Eli Lilly's commitment to sustaining leadership in the obesity therapeutics market beyond tirzepatide's initial success. The Phase 3 trial design using tirzepatide as the active comparator—rather than placebo—indicates confidence in advancing to a next-generation therapy and suggests Eli Lilly anticipates demonstrating clinically meaningful superiority or differentiation.
Competitive Implications: Success of retatrutide would further consolidate Eli Lilly's dominance in the GLP-1/GIP dual-agonist class and potentially extend market exclusivity in the obesity indication. The program positions Eli Lilly to capture additional market share as obesity treatment demand grows globally and tirzepatide uptake accelerates post-approval across multiple regions.
Future Catalysts: Phase 3 trial completion and data presentation represent the critical near-term catalyst. Regulatory filing timelines and approval decisions in the US, EU, and Japan will follow. Label expansion potential (e.g., cardiovascular outcomes, metabolic syndrome) and combination therapy strategies may emerge post-approval.
Expected Milestones: Phase 3 data readout; regulatory submissions to FDA, EMA, and PMDA; potential approval decisions (timelines not disclosed); commercial launch planning. Patent protection and exclusivity periods for retatrutide have not been disclosed.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.